2026-05-02T19:14:26Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/227892024-11-29T03:17:07Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967

00925njm 22002777a 4500 dc Toledo Pons, Nuria author van Boven, Job FM author Roman-Rodriguez, Miguel author Perez, Noemi author Valera Felices, Jose Luis author Soriano, Joan B author García-Cosío, Borja author 2019-01-24 Background Asthma-COPD overlap (ACO) is a term that encompasses patients with characteristics of two conditions, smoking asthmatics or COPD patients with asthma-like features such as high bronchodilator response or blood eosinophil count. 300 cells/mu L. The aim of this study was to compare the different phenotypes inside the ACO definition in a real-life population cohort. Methods We analyzed patients from the MAJORICA cohort who had a diagnosis of asthma and/or COPD based on current guidelines, laboratory data in 2014 and follow-up until 2015. Prevalence of ACO according to the different criteria, demographic, clinical and functional characteristics, prescriptions and use of health resources data were compared between three groups. Results We included 603 patients. Prevalence of smoking asthmatics was 14%, COPD patients with high bronchodilator response 1.5% and eosinophilic COPD patients 12%. Smoking asthmatics were younger and used more rescue inhalers, corticosteroids and health resources. Conversely, eosinophilic COPD patients were older than the other groups, often treated with corticosteroids and had lower use of health resources. Most of the COPD patients with high bronchodilator response were included in the eosinophilic COPD group. Conclusions ACO includes two conditions (smoking asthmatics and eosinophilic COPD patients) with different medication requirement and prognosis that should not be pooled together. Use of >= 300 blood eosinophils/mu L as a treatable trait should be recommended. Toledo-Pons N, Van Boven JFM, Román-Rodríguez M, Perez N, Valera Felices JL, Soriano JB, et al. ACO: Time to move from the description of different phenotypes to the treatable traits. PLoS One. 2019 Jan 24;14(1):e0210915. 10.1371/journal.pone.0210915 1932-6203 PloS One http://hdl.handle.net/20.500.13003/8901 30677059 L626053243 2-s2.0-85060467390 https://hdl.handle.net/20.500.12105/22789 456700400034 ACO: Time to move from the description of different phenotypes to the treatable traits